Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 437 results for "Victoza"

CHMP recommends nine new drugs
Pharma Times

CHMP issues positive opinion for expanded use of Tresiba & Vic...

The Committee for Medicinal Products for Human Use (CHMP) issued positive opinions for expanded use of Tresiba (insulin degludec) and Victoza (liraglutide) in type 2 diabetes. Once the European Commission approves the label expansion, physicians ... PharmaBiz, 3 weeks ago
Tresiba and Victoza Receive CHMP Decisions for Expanded Use American Journal of Public Health, 4 weeks ago
[x]  

15 images for Victoza

PitchEngine, 3 weeks ago
PitchEngine, 3 weeks ago
PitchEngine, 3 weeks ago
PitchEngine, 3 weeks ago
Charles Ayoub, 3 weeks ago
Pharma Times, 1 month ago
Nordic Life Science, 1 month ago
Black Press USA, 1 month ago
Business Insider, 1 month ago
PRWeb, 2 months ago

Victoza (Obesity) - Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/dxdmrx/victoza_obesity) has announced the addition of the "" report to their offering. After a more than decade-long dormancy, the obesity market is undergoing a revival with the ...
 Individual.com2 weeks ago Research and Markets: Victoza (Obesity) - Forecast and Market Analysis to 2022  TMC Net2 weeks ago RESEARCH AND MARKETS : Victoza (Obesity) - Forecast and Market Analysis to 2022  4 Traders2 weeks ago Global Obesity Therapeutics Market 2013-2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity  Individual.com1 week ago
[x]  
Business Insider

Lilly weekly diabetes drug succeeds vs market leader Victoza -study

By (Reuters) - An experimental once-weekly medicine for type 2 diabetes developed by Eli Lilly and Co proved as effective in lowering blood sugar as Victoza from Danish drugmaker Novo Nordisk in an eagerly anticipated late stage study. The Lilly ...
 Business Insider1 month ago Lilly weekly diabetes drug as effective as market leader Victoza-study  Reuters1 month ago UPDATE 1-Lilly weekly diabetes drug as effective as market leader Victoza-study  Reuters UK1 month ago Lilly Diabetes Drug Could Breathe New Life into Pipeline  Pharmaceutical Manufacturing Magazine1 month ago
[x]  

Who loses most in Lilly vs. Novo diabetes study? AstraZenecaby Tracy Staton

Novo Nordisk's Victoza--FiercePharma file photo Eli Lilly is one step closer to launching its promising new diabetes drug dulaglutide--and one step closer to putting a crimp in Novo Nordisk's big-selling rival, Victoza . Lilly unveiled top-line ...
 FiercePharma1 month ago Lilly's diabetes drug matches Victoza  Pharmafocus1 month ago Study: Eli Lilly's dulaglutide non-inferior to Novo Nordisk's Victoza  FirstWord Pharma1 month ago Lilly Diabetes Drug Is as Good as Novo Market Leader Victoza  Washington Post1 month ago
[x]  

Physician Views: A Victoza competitor in waiting? Can Eli Lilly's dulaglutide make an impact in the GLP-1 agonist market?

Last week, Eli Lilly confirmed that in the head-to-head AWARD-6 study its experimental GLP-1 agonist dulaglutide demonstrated 'non-inferiority' to Novo Nordisk's market-leading Victoza brand . Dulaglutide is the first alternative drug in the ...
 FirstWord Pharma1 month ago Intranasal GLP-1 Promising in Pilot Study in Type 2 Diabetes  Medscape2 weeks ago
Pharma Times

Lillys diabetes drug dulaglutide matches Novos Victoza

Eli Lilly has been boosted by data from a head-to-head study which shows that its investigational GLP-1 glucagon-like peptide 1 receptor agonist dulaglutide is as effective as the market-leader
 Big News Network1 month ago Lilly's diabetes drug dulaglutide matches Novo's Victoza  Pharma Times1 month ago Is Eli Lilly's Bad News Priced In?  Motley Fool1 month ago Eli Lilly's Dulaglutide: The Same, But Better  Motley Fool1 month ago
[x]  

FDA and EMA join forces to diffuse safety cloud over Januvia, Victoza & Co.

Merck's ($MRK) Januvia, Novo Nordisk's ($NVO) Victoza and their brethren are in the clear. After a new round of safety reviews, U.S. and European regulators found little evidence that widely used diabetes drugs known as incretin mimetics cause ...
 FiercePharma1 month ago

Clock Is Ticking For AstraZeneca

thought Victoza would do ok until Bydureon came along as Victoza is a once-daily injection compared to Byetta which is injected twice-daily and was the only approved GLP-1 back when Victoza came
 Big News Network1 month ago
Medical Marketing And Media

Lilly's dulaglutide hits the mark for comparability to Victoza in a blockbuster showdown

Enrique Conterno, president of Lilly Diabetes Eli Lilly says its closely watched GLP-1 diabetes drug dulaglutide works as well as the market leading therapy Victoza, but isn't superior to the rival drug. That's going to be good enough for Lilly ...
 FierceBiotech1 month ago Lilly's GLP-1 contender takes a step forward  Medical Marketing And Media1 month ago
PRWeb

Byetta Lawsuit News: Federal Incretin Mimetic Litigation Adds 30 Cases...

The Firm is actively evaluating Byetta lawsuit claims on behalf of diabetics who allegedly developed pancreatitis, pancreatic cancer or thyroid cancer after taking the incretin mimetic. More than 30 federal cases have joined a federal diabetes drug ...
 PRWeb20 hours ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Victoza
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less